Related Experiment Video
Updated: Jun 22, 2026
Longitudinal Morphological and Physiological Monitoring of Three-dimensional Tumor Spheroids Using Optical Coherence Tomography
Published on: February 9, 2019
Three-dimensional tissue models for drug discovery and toxicology
Francesco Pampaloni1, Ernst H K Stelzer, Andrea Masotti
1Cell Biology & Biophysics Unit, European Molecular Biology Laboratory, Meyerhofstrasse 1, Heidelberg, Germany. pampalon@embl.de
Abstract:
Launching a new drug on the market is an extremely time-consuming and expensive process. The total costs from the lab bench to the patient's bedside are in the range of $800 million for each new compound. Innovative pre-clinical assays are urgently needed to select the most promising drug candidates. High-throughput molecular screening does not provide information on the effects on cellular functions. Testing on animals is expensive, ethically controversial, and poorly predictive of the response in humans. Conventional two-dimensional (2D) cellular assays do not accurately reflect the drug response in vivo. To overcome these limitations, biotechnologists are developing three-dimensional (3D) cultures. 3D cultures provide more accurate compound screening and can eliminate toxic and ineffective substances at an early stage. Moreover, 3D cultures can accomplish the 3R agenda (refinement, reduction, and replacement) for the replacement of toxicity testing on animals. We provide an up-to-date overview on the patents in the field.
Insights
Innovative three-dimensional (3D) cultures offer a more accurate and ethical approach to drug development. These advanced models improve preclinical compound screening, reducing costs and animal testing while enhancing human response prediction.
Area of Science:
- Biotechnology and Pharmaceutical Sciences
- Drug Discovery and Development
- Cellular Biology and Toxicology
Background:
- Drug development is a lengthy and costly process, with preclinical stages demanding innovative solutions.
- Current high-throughput screening and traditional 2D cell assays lack predictive accuracy for in vivo drug responses.
- Animal testing presents ethical concerns and limited translatability to human outcomes.
Purpose of the Study:
- To review and highlight the patent landscape of three-dimensional (3D) cell culture technologies.
- To emphasize the advantages of 3D cultures in improving preclinical drug candidate selection.
- To showcase 3D cultures as a method to reduce reliance on animal testing in drug safety evaluations.
Main Methods:
- Review of recent patents related to three-dimensional (3D) cell culture techniques for drug screening.
- Analysis of how 3D culture systems address limitations of traditional assays and high-throughput screening.
- Evaluation of 3D cultures in the context of the 3Rs agenda (refinement, reduction, replacement) for animal testing.
Main Results:
- 3D cell cultures provide a more physiologically relevant model for assessing drug efficacy and toxicity.
- These advanced models enable more accurate prediction of drug responses in humans compared to 2D assays.
- 3D culture technologies are patented, indicating significant investment and development in this area.
Conclusions:
- Three-dimensional (3D) cell cultures represent a significant advancement in preclinical drug screening.
- Adoption of 3D cultures can lead to more efficient, cost-effective, and ethically sound drug development.
- The patent overview confirms the growing importance and innovation surrounding 3D cell culture technologies.
